HALLE/SAALE, Germany, March 26th, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, the Company’s chief financial officer, will provide an update of corporate, scientific and clinical accomplishments at BioCapital Europe 2014 in Amsterdam. Dr Liebers` presentation will take place on Thursday, March 27th, at 11:20 am CET at the Sofitel Legend The Grand Amsterdam.
BioCapital Europe is Europe’s premier life sciences investment conference, offering VCs and Institutional Investors unique and timely access to exciting biotech companies from the Benelux and Europe. Attendance is by invitation only. For more information on the conference, please visit www.biocapitaleurope.com/BioCapitalEurope/.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900